<SEC-DOCUMENT>0000912282-16-000495.txt : 20160106
<SEC-HEADER>0000912282-16-000495.hdr.sgml : 20160106
<ACCEPTANCE-DATETIME>20160106124715
ACCESSION NUMBER:		0000912282-16-000495
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160106
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160106
DATE AS OF CHANGE:		20160106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AntriaBio, Inc.
		CENTRAL INDEX KEY:			0001509261
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				273440894
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-54495
		FILM NUMBER:		161326044

	BUSINESS ADDRESS:	
		STREET 1:		1450 INFINITE DRIVE
		CITY:			LOUISVILLE
		STATE:			CO
		ZIP:			80027
		BUSINESS PHONE:		650-847-1919

	MAIL ADDRESS:	
		STREET 1:		1450 INFINITE DRIVE
		CITY:			LOUISVILLE
		STATE:			CO
		ZIP:			80027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FITS MY STYLE INC
		DATE OF NAME CHANGE:	20110104
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>antriabio8k_010616.htm
<TEXT>
<html>
<head>
    <title>antriabio8k_010616.htm</title>
    <!--Licensed to: Dorsey & Whitney LLP-->
    <!--Document Created using EDGARizer 2020 5.5.2.0-->
    <!--Copyright 1995 - 2015 Summit Financial Printing. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">
<br>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">UNITED STATES</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">WASHINGTON, D.C. 20549</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">FORM 8-K</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">CURRENT REPORT</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Date of Report (Date of earliest event reported): January 6, 2016</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline"><font style="TEXT-DECORATION: underline; DISPLAY: inline">ANTRIABIO, INC.</font></font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">(Name of registrant in its charter)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="29%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; TEXT-DECORATION: underline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline"><font style="DISPLAY: inline">Delaware</font></font></div>
</td>
<td valign="top" width="21%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; TEXT-DECORATION: underline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline"><font style="DISPLAY: inline">000-54495</font></font></div>
</td>
<td valign="top" width="28%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; TEXT-DECORATION: underline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline"><font style="DISPLAY: inline">27-3440894</font></font></div>
</td>
</tr><tr>
<td valign="top" width="29%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">(State or jurisdiction</font></div>
</td>
<td valign="top" width="21%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">(Commission File</font></div>
</td>
<td valign="top" width="28%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">(IRS Employer</font></div>
</td>
</tr><tr>
<td valign="top" width="29%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">of incorporation or</font></div>
</td>
<td valign="top" width="21%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Number)</font></div>
</td>
<td valign="top" width="28%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Identification No.)&#160;</font></div>
</td>
</tr><tr>
<td valign="top" width="29%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">organization)&#160;</font></div>
</td>
<td align="left" valign="top" width="21%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="top" width="28%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">1450 Infinite Drive</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Louisville, CO 80027</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;(Address of principal executive offices)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">(303) 222-2128</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;(Registrant's telephone number)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;(Former name or former address, if changed since last report)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: wingdings; DISPLAY: inline">o</font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: wingdings; DISPLAY: inline">o</font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: wingdings; DISPLAY: inline">o</font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: wingdings; DISPLAY: inline">o</font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<br>
<div id="PGBRK" style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>

<div id="PN" style="WIDTH: 100%; PAGE-BREAK-AFTER: always">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">Item 7.01. Regulation FD Disclosure.</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">On January 6, 2016, we issued the press release attached hereto as Exhibit 99.1.&#160;&#160;In accordance with General Instruction B.2 of Form 8-K, the information set forth herein and in the press release is deemed to be &#8220;furnished&#8221; and shall not be deemed to be &#8220;filed&#8221; for purposes of the Securities Exchange Act of 1934, as amended.&#160;&#160;The information set forth in Item 7.01 of this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">Item 9.01 Financial Statements and Exhibits</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="7%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline">EXHIBIT</font></div>
</td>
<td align="left" valign="middle" width="71%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline">DESCRIPTION</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="7%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">99.1</font></div>
</td>
<td align="left" valign="middle" width="71%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Press Release of AntriaBio, Inc. dated January 6, 2016 **</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">** The following exhibit relating to Item 7.01 is intended to be furnished to, not filed with, the SEC pursuant to Regulation FD.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<br>
<div id="PGBRK" style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>

<div id="PN" style="WIDTH: 100%; PAGE-BREAK-AFTER: always">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">SIGNATURES</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="37%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160;&#160;</font></div>
</td>
<td align="left" colspan="2" valign="top" width="40%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline">ANTRIABIO, INC.</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="37%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160;&#160;</font></div>
</td>
<td align="left" valign="middle" width="4%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="middle" width="36%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160;&#160;</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="37%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160;&#160;</font></div>
</td>
<td align="left" valign="middle" width="4%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="middle" width="36%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160;&#160;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="37%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">DATE:&#160;&#160;January 6, 2016</font></div>
</td>
<td align="left" valign="top" width="4%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">By:</font></div>
</td>
<td align="left" valign="top" width="36%" style="BORDER-BOTTOM: black 1px solid">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"><font style="DISPLAY: inline">/s/ Morgan Fields</font><font style="DISPLAY: inline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="37%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="top" width="36%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Morgan Fields</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Chief Accounting Officer</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<br>
<div id="PGBRK" style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>

<div id="PN" style="WIDTH: 100%; PAGE-BREAK-AFTER: always">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">EXHIBIT INDEX</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="7%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline">EXHIBIT</font></div>
</td>
<td align="left" valign="middle" width="71%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline">DESCRIPTION</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="7%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">99.1</font></div>
</td>
<td align="left" valign="middle" width="71%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Press Release of AntriaBio, Inc. dated January 6, 2016 **</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">** The following exhibit relating to Item 7.01 is intended to be furnished to, not filed with, the SEC pursuant to Regulation FD.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<br>
<div id="PGBRK" style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>

<div id="PN" style="WIDTH: 100%; PAGE-BREAK-AFTER: always">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>
</div>

<br>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99_1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head>
    <title>ex99_1.htm</title>
    <!--Licensed to: Dorsey & Whitney LLP-->
    <!--Document Created using EDGARizer 2020 5.5.2.0-->
    <!--Copyright 1995 - 2015 Summit Financial Printing. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">
<div style="TEXT-ALIGN: right"><font style="FONT-WEIGHT: bold">EXHIBIT 99.1</font></div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><img src="logo.jpg" alt=""><br>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">AntriaBio Announces Appointment of Michael Deperro as Vice President of Operations</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline"><font style="FONT-WEIGHT: bold; DISPLAY: inline">LOUISVILLE, CO &#8211; (MarketWired) &#8211; January 6, 2016 &#8211; </font><font style="TEXT-DECORATION: underline; FONT-WEIGHT: bold; DISPLAY: inline">AntriaBio, Inc.</font><font style="FONT-WEIGHT: bold; DISPLAY: inline"> (&#8220;AntriaBio&#8221; or the &#8220;Company&#8221;) (OTCQB: ANTB),</font> a biopharmaceutical corporation developing novel extended release therapies, announced today that Michael Deperro has joined the Company as Vice President of Operations. In his role, reporting directly to the Company&#8217;s Chief Executive Officer (CEO), Mr. Deperro will oversee operations including manufacturing, engineering and facilities.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Mr. Deperro brings to AntriaBio a wealth of experience directing operations supporting the clinical and commercial development of several complex compounds at pharmaceutical companies as well as contract manufacturing and development organizations. As former Director of Manufacturing at Alkermes, Mr. Deperro led manufacturing operations for three long-acting injectable products &#8211; Risperdal<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; DISPLAY: inline">&#174; </font>Consta<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; DISPLAY: inline">&#174;</font>, Vivitrol<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; DISPLAY: inline">&#174; </font>and Bydureon<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; DISPLAY: inline">&#174;</font>. The addition of Mr. Deperro to the management team will further support AntriaBio&#8217;s ability to achieve future potential clinical, regulatory and commercial milestones.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Mr. Deperro stated, &#8220;I am thrilled to join the AntriaBio team as the Company prepares to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for AB101 and initiate a clinical study in type 1 and type 2 diabetes patients. I look forward to collaborating with the team to achieve critical milestones for AB101, AB301 and other pipeline therapies in development.&#8221;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#8220;We are very excited to have Michael join us as we continue to produce cGMP AB101 for our upcoming clinical study,&#8221; stated Nevan Elam, Chairman and Chief Executive Officer. &#8220;In addition to his insights and direction, Michael&#8217;s experience with long-acting injectable therapies and microsphere formulations in particular, will be instrumental as we ramp up operations over the next 12 months.&#8221;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">About AntriaBio, Inc.</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">AntriaBio is a biopharmaceutical company that develops novel extended release therapies by combining proprietary formulation and manufacturing capabilities with well-known molecules to significantly improve standards of care. AntriaBio's lead product candidate is AB101, an injectable once-weekly basal insulin for type 1 and type 2 diabetes that addresses a $11 billion market where the current standard of care is a once-daily basal insulin injection. For more information visit:&#160;<font style="TEXT-DECORATION: underline; DISPLAY: inline">www.antriabio.com</font>.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">Forward-Looking Statements</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">This release, like many written and oral communications presented by AntriaBio, Inc., and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of the Company, are generally identified by use of words "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, AntriaBio undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">AntriaBio, Inc. Contact:</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Noopur Liffick</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">VP of Corporate Development</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">(650) 549-4175</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline"><font style="TEXT-DECORATION: underline; DISPLAY: inline">investor-relations@antriabio.com</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Source: AntriaBio, Inc.</font></div>

<br>
<div id="PGBRK" style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>

<div id="PN" style="WIDTH: 100%; PAGE-BREAK-AFTER: always">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>
</div>

<br>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
M      !@     0   &     !4&%I;G0N3D54('8U+C P /_; $,  @$! @$!
M @(" @(" @(#!0,# P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*#0H*"PP,
M# P'"0X/#0P."PP,#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( #4
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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M17,_&?QAJGP^^$?B;7=%TF37M8T?3+B\LM.3.Z]FCC9DC&.?F( XY]*^6_\
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M>"O&=YH$GBJ35=2TO_C_ %T;3+K5(]/Y(/G26\;HF,'.3Q@^E>A>)/CYX/\
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M?E'\ HC_ ,%*?^"UVM^,IE-YX-^&\IGM0ZYC,5J?*M1@_P#/2;,V/]ZOI_\
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M.IMX9''WD3YY7SZ<*/J&]*] \?\ PY\8?M27EK8ZY8OX-\&VLPFFMGG2:^U
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0B@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
